News & Updates
SOLVD Health Receives New York State Laboratory Approval
December 24, 2024 – SOLVD Health announces approval from the New York State Department of Health Clinical Laboratory Evaluation Program (CLEP) for its San Diego-based laboratory.
SOLVD Health to Present at William Blair’s Innovator Series
December 10, 2024 — SOLVD Health announces that its Founder and CEO, Dr. Keri Donaldson, will provide a company update and participate in a virtual fireside chat at William Blair’s Innovator Series: Life Science Tools and Diagnostics.
SOLVD Health Launches 5-Year Post-Approval Study on Real-World Impact for AvertD® Genetic Test
November 18, 2024 — SOLVD Health has launched a comprehensive post-approval study for AvertD®, the first U.S. Food and Drug Administration (FDA)-approved genetic test for assessing risk of developing opioid use disorder (OUD). This study aims to expand upon pivotal study findings and further demonstrate AvertD’s ability to enhance personalized data-driven decisions in real-world settings.
SOLVD Health Receives FDA PMA Supplement Approval for Use of INFINITI High-Throughput System with AvertD®
November 12, 2024 — SOLVD Health, a patient intelligence company developing cutting-edge precision solutions to deliver better health outcomes, has received U.S. Food and Drug Administration (FDA) PMA supplement approval for its INFINITI High Throughput System (HTS) to be used with AvertD®.
SOLVD Health Names Chief Financial Officer and Senior Vice President of Clinical Operations
August 13, 2024 — SOLVD Health, a patient intelligence company focused on creating innovative technologies that identify an individual’s risk of disease by discovering and converting biological signals into predictive, contextual health insights, has appointed Mark Hazeltine as Chief Financial Officer and Ron McCullough as Senior Vice President of Clinical Operations.
FDA Approves First Test to Help Identify Elevated Risk of Developing Opioid Use Disorder
December 19, 2023 — Today, the U.S. Food and Drug Administration approved the first test that uses DNA in assessing whether certain individuals may have an elevated risk of developing opioid use disorder (OUD).
SOLVD Health CEO Named Clinical Scientist of the Year by the Association of Clinical Scientists
June 1, 2021 — Dr. Keri Donaldson was recognized by his peers for his outstanding contributions to clinical science in research, teaching, and service.
SOLVD Health Prepares to Launch Clinical Study of Non-Invasive Colorectal Cancer Screening Test
January 6, 2021 — The PREVENT clinical trial will enroll up to 12,000 individuals to validate the test, LifeKit Prevent, for the detection of colorectal cancer and adenomas. Subjects will include adults at average-risk for colorectal cancer between the ages of 45 and 84.
Prescient Medicine Holdings is Now SOLVD Health
December 1, 2020 — The new name and brand reflect the company’s mission to solve some of healthcare’s biggest challenges through preventative health solutions that combine genetics-based patient insights with cutting-edge technologies.
Management Solutions for Opioid Epidemic Are Similar to Management of the COVID-19 Pandemic
September 21, 2020 — Pharmacy Times® interviewed Keri Donaldson, medical director and CEO of Prescient Medicine, about the effects of the current coronavirus disease 2019 (COVID-19) pandemic on the ongoing opioid epidemic in the United States.